Doxorubicin as a Potential Treatment Option in Canine Mammary Tumors.
Luciana Mădălina GhermanOana ZanoagaLiviuta BudisanLajos-Zsolt RadulyIoana Berindan NeagoePublished in: Veterinary sciences (2023)
Canine mammary tumors represent one of the leading malignant pathologies in female dogs, displaying the importance of efficient therapeutic findings, besides the golden-standard surgery, able to limit the development of the disease. Studies in human cancers demonstrated that Doxorubicin presents a good effect in different biological processes like apoptosis, autophagy, the cell cycle, cell invasion, and the epithelial-to-mesenchymal transition. This study followed the effects of Doxorubicin on two canine mammary cancer cell lines P114 and CMT-U27. Doxorubicin treatment in both cell lines shows an inhibitory effect in cell proliferation and an alteration in expression of the EMT-related genes. The obtained results provide valuable information for revealing the link between Doxorubicin, phenotypic changes, and proliferation dynamics in canine mammary tumor models.
Keyphrases
- cell cycle
- cell proliferation
- drug delivery
- cancer therapy
- cell death
- endoplasmic reticulum stress
- oxidative stress
- signaling pathway
- endothelial cells
- minimally invasive
- poor prognosis
- epithelial mesenchymal transition
- healthcare
- coronary artery disease
- young adults
- combination therapy
- pi k akt
- long non coding rna
- acute coronary syndrome
- health information
- human health
- social media
- surgical site infection
- replacement therapy